

# Nanomedicine

## A recent trend of drug-nanoparticles in suspension for the application in drug delivery

Journal:	<i>Nanomedicine</i>
Manuscript ID	NNM-2016-0238.R1
Manuscript Type:	Review
Keywords:	Targeting, Nanomaterials, Controlled drug release

SCHOLARONE™  
Manuscripts

View Only

**A recent trend of drug-nanoparticles in suspension for the application in drug  
delivery**

Gurpreet S. Suri<sup>1\*</sup>, Amritvir Kaur<sup>1</sup>, Tapas Sen<sup>1\*</sup>

\*corresponding authors details

<sup>1</sup> Nano-biomaterials Research Group ([www.senlabs.org](http://www.senlabs.org))

School of Physical Sciences & Computing

Centre of Materials Sciences,

University of Central Lancashire,

Preston, PR1 2HE, United Kingdom

Tel: +44 1772894371

Email: [tсен@uclan.ac.uk](mailto:tсен@uclan.ac.uk) or [gurpreetbunny@gmail.com](mailto:gurpreetbunny@gmail.com)

## ABSTRACT

Persistent development in nanomedicine has enabled successful nano-sizing of most drug samples, which in turn imparts remarkable properties to the drugs such as enhanced solubility and bioavailability for the applications in drug delivery. In this context, several review articles are available in scientific domain covering inorganic nanoparticles such as Au, Ag, SPIONs, Qdots, carbon nanotubes and graphene however this review covers the development of drug nanoparticles together with their possibilities and limitation from fabrication (bottom up vs top down) to application in drug delivery during the last 5 years. In addition, some distinguished studies and novel drug particles are presented in order to contribute significantly towards the understanding of drug nanocrystals and its use in drug delivery.

Keywords: Nano-suspension, Amorphous / Crystalline nanoparticles, Top down / Bottom up, Drug-nanocrystals, Nano-carriers, Drug Delivery

## Introduction

Modern material science is no longer restricted to the metallurgical application, as the advancement in the nanotechnology is opening unlocked doors in various fields. For over a decade, extensive research is being undertaken using nanoparticles for its application in medicines, environmental projects, electrical and electronics, aerospace and lifestyle industries. These nanoparticles of nanometer in size ranging from 1 to 1000 nm possess great advantages as compared to the microsized particles.

Development of a large number of drugs and their delivery without any side effects to the patients are the real challenges faced by scientific community. Most of the drug molecules are large organic molecules and have poor solubility in water. Hence a huge effort has been made for nanosizing the drug particles in either an amorphous or crystalline nanosuspension for applications in passive targeting due to enhanced membrane diffusion. Similarly an effort has been made for the development of several carriers for delivering drugs and functionalisation of carriers to enhance the active delivery at a target organ. Furthermore, the nanosize of drug particles imparts remarkable properties to the drugs such as enhanced solubility and bioavailability. Therefore this review is focussed on critically highlighting the nanomedical use of various drug nanocrystals, especially for drug delivery applications.

## Recent trends

Nanoparticles' use has increased exponentially for the drug formulations and drug delivery in the last decade. Increased efforts are applied to monitor the structure – function relationship of the nanoparticles for targeted drug delivery applications. There has been some novel nanodrugs produced recently such as the Copazone, Welchol, VivaGel and RenaGel. Copazone is a random co-polymer of the four main amino acids which is employed to treat muscular sclerosis <sup>[1]</sup>. Welchol is a drug which helps to lower the low density lipoprotein (LDL) cholesterol and blood sugar level by binding the cholesterol <sup>[2]</sup>. VivaGel is a topically administered vaginal virucide which is a multivalent lysine based dendrimer product <sup>[3]</sup>. RenaGel is an oral polymeric sequestrant that binds to phosphate and is used to treat chronic kidney disease <sup>[4]</sup>. In addition, a timeline is reviewed in Figure 1 to show the FDA approved amorphous and crystalline drugs since 1984 <sup>[5]</sup>.

## Timeline of FDA approvals





Figure 1: Timeline reviewing FDA approved crystalline & amorphous drugs  
(Reproduced with permission from ref [5])

Most of the current cancer therapies and drug formulations are based on the nanoparticle approach to improve the bioavailability and solubility of the encapsulated drugs at the target site. There is an increased use of nanosuspensions for drug delivery application, especially for topically administered drugs since nanosuspensions increases the bioavailability of drugs due to increased permeation. For instance, as shown in Figure 2, nanosuspensions exhibit higher permeability and high concentration gradient for both topical and subcutaneously administered drugs compared to microparticles [6]. A multi-disciplinary principle is employed nowadays to tailor the nanoparticles in order to incorporate specific properties, such as DNA functionalisation using molecular biology and genetics, ion conductivity using the semiconductor physics, solubility and stability using the organic chemistry, and so on. For example,  $\beta$ -Lapachone or simply  $\beta$ -Lap is a novel anticancer drug demonstrated to be delivered by 30 nm PEG-PLA polymer micelles to the lungs of mice. The drug was injected intravenously and was bioactivated by the enzyme NAD(P)H:quinon oxidoreductase-1 (NQO1) that is found in excess levels at the non-small-cell lung cancer sites [7].




**Figure 2:** Scheme showing enhanced permeability of drug nanosuspension

### **Drug particles in Nanosuspension**

In simple terms, a submicron colloidal dispersion of the nanoparticles (in either amorphous or crystalline form) is called as a nanosuspension. A drug specific nanosuspension consists of dispersed, finely colloidal and mostly biphasic drug particles with an overall size of less than 500 nm<sup>[8]</sup>. These drug-nanoparticles conjugates can be stabilised using polymers and surfactants before administration through various routes such as topical, oral, pulmonary, ocular or parenteral<sup>[6]</sup>. Different ingredients are used for formulation of nanosuspensions such as organic solvents, cosurfactants, stabilisers and other additives such as salts, polyols, buffers, cryoprotectants and osmogents<sup>[9]</sup>.

Solubility and bioavailability of drugs are the key issues that are mitigated using the nanosuspensions. In addition, the nanosuspension also affects the drug's pharmacokinetics that can improve its efficacy and safety. Both chemical and physical modifications are applied to improve the solubility and bioavailability of drugs<sup>[10]</sup>. Chemical modifications include synthesising the soluble salts and prodrugs, whereas the physical modifications include reducing particle size, use of

1  
2  
3 surfactants for solubilisation/complexation, forming pseudo-polymorphs/polymorphs  
4 and preparing drug dispersions <sup>[11-15]</sup>. Different types of composite structure results  
5 from nanoparticles in suspension, as shown in **Figure 3**. Various factors and  
6 techniques are responsible to form composite structures such as the core shell,  
7 internal dispersion, agglomeration, coating/surface modification, hollow, porous,  
8 nano-dense body, nano-porous body and nano-thin film <sup>[16]</sup>.  
9  
10  
11  
12  
13



48  
49  
50 **Figure 3:** Types of composite structures formed from nanoparticles in suspension  
51

### 52 **Functionalisation of nanocrystals**

53 A schematic review of the various ligands surface functionalised on a nanocrystals  
54 core is shown in Figure 4 <sup>[17]</sup>. It can be seen that a drug nanocrystal core can be  
55 surface modified for specific applications by tailoring the type of ligands attached to it  
56  
57  
58  
59  
60

with the help of a polymer coating. For instance, magnetic ligands can be used for magnetically targeting to tumor sites followed by hyperthermia applications, where the drug could be released systematically due to localised heating. The use of image contrast ligand facilitates the diagnostic monitoring of drug release and provide real time data about the pharmacokinetics of the drug. Furthermore, the surface of nanocrystal core could be functionalised with uptake, targeting or adhesion ligands to provide an active transport or targeting to tumor sites in *in vivo*. For instance, nanocrystal implants are exploiting these surface functionalised drug nanocrystals as therapeutic vehicles to identify, transfect and rebuild damaged regions in the body [18].





Figure 4: Surface functionalization of nanocrystals (Reproduced with permission from ref [17])

### Methods of preparation of nanosuspension

Nanosuspensions can be prepared using both bottom-up and top-down approaches. These methodologies are widely applied in nanomedicine due to its consistency to produce nanoparticles of controlled aspect ratio [19]. The bottom-up methods are called as conventional precipitation methods whereas the top-down methods are referred to as disintegration methods. The top-down methods are further classified as media milling and high pressure homogenisation (HPH) methods, where the latter

is sub-classed into DissoCubes (HPH in water), Nanopure (HPH in nonaqueous media) and Nanoedge (HPH and precipitation) <sup>[20]</sup>. Figure 5 present a schematic diagram of two different approaches for the fabrication of drug nanoparticles.



**Figure 5:** Various methods of nanosuspension preparation

Top down method of nanosuspension preparation aims to reduce particle size into nanoparticles using wet milling techniques such as high pressure homogenisation, microfluidisation and media milling. There are no harmful solvents used in these techniques but media milling method requires high energy inputs <sup>[21]</sup>. In general, considerable amounts of heat is generated in the top down methods leading to destruction of heat sensitive drug components. For example, milling is reported to cause mechanical activation at surfaces of drug particles <sup>[22]</sup>. High surface energetics lead to generation of amorphous regions and crystal defects. Further crystallisation of the drug particles reduces the physical and chemical stability of particles on storage <sup>[23]</sup>.

1  
2  
3 Bottom up method of nanosuspension preparation aims to produce nanoparticles  
4 from precipitate by first dissolving the drug in an organic solvent followed by adding a  
5 precipitating agent in the presence of a stabiliser [24]. Some forms of this method  
6 include supercritical fluid processes, solvent anti-solvent method, emulsion solvent  
7 evaporation and spray drying. Some of the limitations of bottom up method include  
8 generation of unstable polymorphs, solvates and hydrates of the nanosuspension  
9 constituents [25, 26]. Furthermore, the difficulty of completing removing the solvents  
10 from the final product is persistent in bottom up method. This reduces the physical  
11 and chemical stability of the formulation, as it is often seen that bottom up method  
12 results in needle shaped particles due to rapid unidirectional growth [24].  
13  
14  
15  
16  
17  
18  
19

20 A study of some of the recent nanosuspensions prepared through various routes for  
21 drug delivery is shown in table 1 [27 - 42]. The table highlights both amorphous and  
22 crystalline nanosuspensions along with the particle size, method of preparation and  
23 main conclusions from the studies.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1: A study of the recent (5 years) drug nanoparticles in both crystalline and amorphous forms [27 – 42]

Type of nanoparticle	Particle size (nm)	Drug/Polymer used	Method of preparation	Focus of article	Conclusion	Ref.
Amorphous nanoparticle suspension	350	Cylosporin A (CyA)	Bead milling	Enhance applications in psoriasis or dermal penetration	Higher penetration using amorphous CyA nanoparticles	27
Amorphous nanosuspension	50-500	Isradipine	Sonoprecipitation	Enhance drug delivery for increased dissolution rates	Improved drug release rate was observed	28
Nanosuspension (crystalline to amorphous)	300 -500	Myricetin	Nanosizing process	Effect of stabilizers on bioavailability/ dissolution of poorly water-soluble drugs	Stabilizers enhanced dissolution, amorphisation enhanced solubility	29
Nanosuspension (crystalline to amorphous)	208 -246	Cur-TPGS NSs (Curcumin-D- $\alpha$ -Tocopherol PEG 1000 succinate)	Sonoprecipitation, ultrasonic homogenization	To enhance the solubility of formed nanosuspension	Cur-TPGS NSs showed higher solubility & oral adsorption	30
Nanosuspension (crystalline)	< 150	Anticancer compound, SN 30191	Wet milling	Evaluation of crystalline nanosuspension as a cancer drug	Crystalline nanosuspension showed high tolerance & drug delivery	31
Nanocrystals to Amorphous nanosuspension	150-175	Curcumin	Antisolvent precipitation method	Enhance bioavailability of curcumin by nanosizing and amorphisation	Nanosized & amorphous nanosuspension shows the maximum stability	32
Crystalline nanosuspension	200-350	BCS class II/IV compounds	Spray drying	Enhance dissolution using nanocrystalline suspensions	Faster dissolution was obtained subject to drug-to-excipient ratio	33
Amorphous &	NA	Nanosuspensions	Freeze drying	Effect of critical formulation	Freeze drying does not	34

crystalline nanosuspension		with steric stabilizers		temperature (CFT) and freeze drying on drug's stability	affect drug's stability	
Amorphous & crystalline nanosuspension	300	Hydrocortisone (HC)	Microfluidic nanoprecipitation (bottom-up) & wet milling (top-down)	Bottom up and top down methods for ophthalmic drug	Top-down showed high stability as compared to the bottom-down	35
Crystalline nanosuspension	88, 122, 362	Compounds (celecoxib, griseofulvin, fenofibrate, and compound-X)	Ultracentrifugation & filtration	Dissolution rate dependence on the Noyes-Whitney equation	Low dependence	36
Amorphous and crystalline nanosuspensions	274	Ziprasidone	Lyophilisation and milling	Improving drug absorption in the fasted state (in-vitro studies)	Amorphous nanosuspension showed high absorption	37
Crystalline & amorphous nanosuspension	323-734	Itraconazole (ITZ)	HME and wet milling	Effect of methods on Itraconazole (ITZ) for both <i>in vitro</i> & <i>in vivo</i>	HME method showed higher dissolution & bioavailability	38
Crystalline & amorphous nanosuspension	300	Drug/polymeric complex	Wet-milling	Increase solubility & dissolution rate by nanosizing	Higher solubility & dissolution rate upon nanosizing	39
Amorphous nanosuspension	>600	Ezetimibe nanosuspension	Precipitation	Enhance oral bioavailability of ezetimibe	Amorphous precipitation increases oral bioavailability	40
Crystalline nanosuspension	699	Fenofibrate	Bead-milling method Spray drying	Effect of methods on bioavailability & dissolution	The dissolution was found faster in the spray dried powder	41
Crystalline nanosuspension	397	Indomethacin	Spray drying	Effect of spray drying on powder yields	High yields with lower moisture content	42

### Size measurement of nanoparticles in suspension

The size and number of atoms within a single nanoparticle controls the morphological aspects of these particles, in addition to other chemical and physical properties. For instance, the smallest hydrogen atom has a diameter of about 0.074 nm whereas a lead atom is about 0.32 nm. Therefore in a single nanoparticle, there can be ten to hundreds of atoms present based on the bonding types and composition <sup>[16]</sup>. One of the most important properties attained on transforming micro-sized particles into nanoparticles is the massive increase in the surface area. This increased surface area imparts enhanced solubility and reaction rates for the particles, which is a key desire in modern science. Other properties such as dielectric constant, melting point and even crystal lattice are affected due to the “size effect”.

The size measurement for nanoparticles can be done using a range of characterisation techniques such as imaging using electron microscope from SEM and TEM, peak widths at half maximum from X-ray diffraction, surface area analysis from BET and Brownian motion calculation using Dynamic Light Scattering in Zetasizer instrument. The imaging techniques are considered to be relatively easy and quick as compared to others since it can provide visual inspection of the particles as well. However, the sample preparation is a critical step that determines the quality of image and accuracy of size measurements.

The X-ray method is on the other hand considered complex but relatively precise in estimating the average particle size from peak properties. But on a nanoscale, it is also subjected to limitations of sample preparation and orientation to the electron beam. Surface area analysis from BET is relatively simpler to estimate particle size but the assumption of spherical shape for calculation is not applicable to all types of nanoparticles. Furthermore, the inner structure and surface state of particles can affect the calculations and thereby the size of nanoparticles. The application of Zetasizer is widely recognised in literatures for determining the size of particles in nanosuspensions <sup>[16, 43 - 45]</sup>.

A summary of the most common analytical techniques for characterisation of nanoparticles is shown in the Figure 6. These techniques are helpful in studying various aspects of the nanoparticles such as X-ray diffraction for amorphous or

crystallinity study, SEM/EDX and AFM for surface morphology study, TEM for internal structure study, AGM, VSM and SQUID for magnetic property study and so on.




Figure 6: Useful analytical techniques to study various properties of nanoparticles

### Amorphous vs Crystalline Nanoparticles in Nanomedicine

It is possible to synthesise various drug nanoparticles used in nanomedicine as either amorphous or crystalline forms. On one hand, there is a well-defined crystal structure with some crystal defects located on the surface and bulk of the crystalline nanoparticles. On the other hand, structural disorder is evident throughout the nanoparticles in amorphous state providing a more porous framework with high structural defects [46 - 48]. These structural differences arise due to different methods of nanoparticles preparation. Both bottom up and top down approaches can produce particles with varying crystallinity and other physio-chemical properties.

Most of the drug nanoparticles are prepared using top down approaches, among which high pressure homogenisation (HPH) is widely used. HPH process consists of 3 main steps [49 - 54]:

- Dispersion of powdered drug in a solution of water and stabiliser
- Comminution of coarse particles of drug under low pressure homogenisation to prevent blockage of homogenisation chamber
- High pressure homogenisation using repetitive cycles to attain the desired particle size and distribution

The number of cycles and pressure of homogenisation are the critical factors which control the particle size and distribution. For example, the polydispersity index and particle size of amoitone B nanocrystals is reported to gradually reduce with an increase in number of cycles and homogenisation pressure in a stepwise manner <sup>[52]</sup>. However, once the particles become highly uniform non-aggregated then a continuous increase in the pressure or number of cycles has little effect on particle size and polydispersity index <sup>[52]</sup>.

HPH is also often combined with precipitation process to prepare nanocrystals. In this process, first the precipitation of drug is done in a liquid medium that produces comminuted drug crystals. Then high pressure homogenisation using repetitive cycles is applied to achieve the desired particle size <sup>[55, 56]</sup>. The main requirement of this process is that the drug should dissolve in at least one solvent and get precipitated using a miscible non-solvent. This poses challenges of potential toxicity from solvent media and its complete removal from the final drug preparation <sup>[57]</sup>.

Wet ball milling technique uses a milling chamber to comminute a drug material that is dispersed in water and agitated along with surfactants or stabilisers. In this technique, mechanical shear and attrition is used due to collision of the drug particles with each other, milling media and walls of the milling chamber <sup>[58]</sup>. Small pearls, stainless steel, cross linked polystyrene, glass or ceramic beads of size 0.3 mm or higher are used as milling media. However, the final size of the drug nanoparticles depends on other factors such as viscosity of the dispersion media, concentration of the surfactant, temperature conditions, duration of milling process and properties of drug dispersed <sup>[59]</sup>.

The bottom up process offer smaller particle sizes than most top down approaches but its production scale is also much smaller. The fundamental of this process is precipitation of drug nanocrystals in two steps procedure: nucleation followed by crystal growth <sup>[60]</sup>. Hence it is important to control the nucleation step since if the

1  
2  
3 number of nuclei formed is higher, it will limit the growth of every nuclei. The use of  
4 ultrasound in combination to precipitation process results in cavitation effects which  
5 can speed up the nucleation process and minimize agglomeration <sup>[60, 61]</sup>.  
6  
7

8  
9 Another bottom up process is called as evaporative precipitation in aqueous solution,  
10 where the drugs are dissolved in ethanol at 60°C. The solution is then added  
11 dropwise with constant stirring into water at 0°C. This temperature difference  
12 promotes supersaturation and nucleation which leads to a smaller size as compared  
13 to HPH technique. For example, the anticancer drug riccardin D was prepared as  
14 nanocrystals using evaporative precipitation and HPH technique with a size of 184  
15 nm and 815 nm respectively <sup>[51]</sup>. This study shows that a smaller particle size can be  
16 prepared using evaporative precipitation as a bottom up process which provides a  
17 higher control on particle size.  
18  
19  
20  
21  
22  
23

24  
25 Precipitation techniques of bottom up processes usually produces nanodrugs of  
26 lower crystallinity as various factors affect the polymorphic form of the drug  
27 nanoparticles, such as degree of supersaturation, type of solvent-antisolvent, etc.  
28 Solid state characterisation techniques such as XRD, NMR, DSC and FTIR can be  
29 used to study the crystallinity and other properties. However, the amorphous state of  
30 the nanoparticles is thermodynamically favourable during precipitation since it  
31 exhibits a metastable state with high energy that imparts quicker solubility of the  
32 drug. But, the property of the drug is also a significant factor to determine the  
33 resulting state of nanoparticles, as some drugs like Ibuprofen mostly precipitates in  
34 crystalline state, whereas Cefuroxime axetil precipitates as amorphous particles <sup>[62,</sup>  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

Table 2. Comparison of amorphous and crystalline nanoparticles

Types of Drug Nanoparticles	Advantages	Disadvantages
<b>Amorphous NPs</b>	Disorderedness improves thermodynamic driving force	Wide size range (nm to $\mu\text{m}$ )
	High water solubility	Abrupt surface areas
	Enhanced Dissolution rate	Low impurity of drug
	High oral absorption	Physical and chemical instability in GI tract
	High saturation solubility (Ex- Chloramphenicol palmitate)	High pharmacokinetic variability
	Ease of production	Low suitability for intravenous routes
<b>Crystalline NPs</b>	Low pharmacokinetic variability in patients	Lattice energy barrier for dissolution limits
	Narrow size range of crystals ( $< 1 \mu\text{m}$ )	Need stabilisation by surfactants
	Physical and Chemical Stability from enzymatic degradation	Aggregation due to high surface area and surface energy
	High Purity and drug loading (100%)	Requires extensive crystallisation steps
	Suitable for intravenous administration	Low oral absorption

### Nanosuspensions for drug delivery

Nanosuspensions are powerful for drug delivery applications and several latest review articles have provided an in depth discussion on the various routes of administration. In brief, it is important to focus on key developments in this area by reviewing strategic articles and routes of administration. For instance, oral drug delivery is one of the most preferred routes of drug administration but is limited due to low oral absorption and bioavailability. Drug nanoparticles in suspension can tackle this problem by increasing the area of absorption under the curve as shown by naproxen nanoparticles with a 218% increase. Danazol – an inhibitor of gonadotropin when used in suspension showed an increased bioavailability of 82.3 as opposed to conventional dispersion of 5.2% [6]. In addition, lyophilised

nanosuspensions offer faster dissolution rate with an increased permeability, as shown in case of oleanolic acid [70]. A schematic diagram shown in Figure 7 highlights the enhanced permeability and retention (EPR) effect of drug nanocrystals, effective for tumour targeted drug delivery [71].




Figure 7: EPR effect; (A) Normal vessel: the narrow gap junctions present in between endothelial cells allow only small molecules to penetrate, screening out colloidal sized particles. Notice the ordered structure of cells in the presence of functional lymphatic drainage. Lymph flow regularly filters out accumulated material. (B) Tumour microenvironment: The vascular endothelium in and around tumour is disjointed, irregular and leaky allowing effective penetration of nanocrystals. Absent or dysfunctional lymphatic vessels further delay clearance of these particles leading to their enhanced accumulation at tumour site (Reproduced with permission from ref [71]).

1  
2  
3 Nanosuspensions are also compatible for parenteral routes of drug administration  
4 like intravenous, interperitoneal and intra-articular. One of the key requirements for  
5 drug molecules administered through parenteral route is to highly soluble or have a  
6 particle size of less than 5  $\mu\text{m}$  to prevent blockage of capillaries. It has been reported  
7 that nanosuspensions have increased the efficiency of parenterally administered  
8 drugs like paclitaxel <sup>[72]</sup>, aphidicolin <sup>[73]</sup>, clofazimine <sup>[74]</sup> and busulfan <sup>[75]</sup>.

9  
10  
11  
12  
13  
14 Pulmonary drug delivery is dependent on the solubility of the drugs in pulmonary  
15 secretions. It is possible to nebulise the aqueous nanosuspensions using ultrasonic  
16 or mechanical nebulisers for delivery to lungs. This can lead to a uniform distribution  
17 of the drug nanoparticle in the aerosol droplet allowing for rapid dissolution and  
18 diffusion in the lungs. Furthermore, the adhesiveness of the drug to the mucosal  
19 membrane will be increased and therefore prolonging the drug's residence time at  
20 the site of absorption. One such example is seen from budesonide drug that was  
21 nebulised successfully using an ultrasonic nebuliser <sup>[6]</sup>.

22  
23  
24  
25  
26  
27  
28 Other key applications include use of nanosuspensions for ocular drug delivery as  
29 shown by dexamethasone study for anti-inflammation activity in rabbit <sup>[76]</sup>, targeted  
30 drug delivery as shown by aphidicolin study against Leishmania-infected  
31 macrophages <sup>[73]</sup>, mucoadhesion of drug for reducing infection as shown by  
32 mucoadhesive Buparvaquone <sup>[6]</sup> and topical drug delivery <sup>[8]</sup>.

### 33 34 35 36 37 ***In vitro* stability of drug nanocrystals**

38 Some of the areas of concern for *in vitro* stability are related to the pharmaceutical  
39 application of drug nanocrystals such as agglomeration, crystal growth and  
40 sedimentation. Drug nanocrystals can undergo amorphisation, especially upon  
41 application of nanosuspension methodologies such as top down and bottom up  
42 approaches <sup>[77]</sup>. Stabilisers are normally used to prevent the agglomeration of drug  
43 nanocrystals but it was found that drug-polymer interactions can substantially reduce  
44 the crystallinity. For instance, a study provided concrete evidence of Naproxen drug  
45 undergoing amorphisation due to the generation of amorphous layer on nanocrystals  
46 surface when subjected to media milling in the presence of hydroxypropyl  
47 methylcellulose <sup>[78]</sup>.

48  
49  
50  
51  
52  
53  
54  
55 Cell culture assays are generally the standardised protocol for evaluating the  
56 performance of drug nanocrystals. However some of the key limitations of these  
57  
58  
59  
60

1  
2  
3 assays are linked to their working conditions and parameters. For instance, a  
4 fundamental limitation of these assays is due to its finite volume and closed system  
5 features. This can greatly affect the therapeutic efficacy and dissolution rate of the  
6 drug depending on the administered dose, especially if it is above the drug's  
7 saturation solubility. This in turn affects the cytotoxicity based on the incubation time,  
8 since the low dissolution rate drugs naturally exhibit lower cytotoxicity effects <sup>[79]</sup>. A  
9 recent study has established these results by showing that longer incubation times  
10 such as 72 hours, for 240 nm Camptothecin's drug nanocrystals showed similar  
11 cytotoxicity results as that to the solution <sup>[80]</sup>.

12  
13 Furthermore, a recent study also established the fact that drug nanocrystals can  
14 aggregate within the cells to form rough edges with time. This can greatly affect the  
15 overall size and shape of the drug nanocrystals and therefore degrade the drug's  
16 pharmacokinetics and its release. For instance, in the study, antiretroviral drug  
17 Ritonavir was loaded as large drug nanocrystals of about 300 to 900 nm into the  
18 macrophages. It was found that 24 hour post uptake, 68% of the drug nanocrystals  
19 were intact due to aggregation and acted as rough edged reservoirs to sustainably  
20 release the drug over a period of 2 weeks and longer <sup>[81]</sup>. As an extension to this  
21 work, it was also found that surfactant coating, shape and type of drug nanocrystals  
22 were influential parameters which affected its release, uptake and antiretroviral  
23 activity. It was found in the study that drug nanocrystals with irregular and round  
24 edges showed low cell uptake, while rod shaped drug nanocrystals showing regular  
25 and smooth edges showed a rapid uptake and release from macrophages <sup>[82]</sup>.

### 40 *In vivo* stability of drug nanocrystals

41 A wide range of factors affect the stability and performance of drug nanocrystals in *in*  
42 *vivo*, such as the dissolution rate, half-life, charge, shape, particle distribution profile  
43 and toxicity effects. Both biological and physicochemical parameters affect the  
44 biodistribution and pharmacokinetics of the drug nanocrystals in *in vivo*. For  
45 instance, a study highlighted the effect of agglomeration on the cell's uptake  
46 efficiency, showing that drug nanocrystals of size 50-100 nm were not internalised by  
47 the cells <sup>[83]</sup>. Furthermore, the un-dissolved drug nanocrystals injected intravenously  
48 remained in blood and interacted with plasma proteins that lead to surface  
49 opsonisation and formation of protein-drug agglomerates. This facilitates the  
50 recognition and clearance of the protein-drug agglomerates from the blood by the  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

tissue macrophages and circulating phagocytes that are directly in contact with blood [84].

Dissolution of the drug nanocrystals and its accumulation in liver and spleen are the key limitations which is inherent of the nanocrystals [85]. There are several studies which demonstrates the dissolution profile of low cytotoxic drug nanocrystals in *in vivo* models such as rats, dogs, rabbits, etc and also pinpoint their accumulation in tissues, especially the macrophages of spleen and Kupffer cells of the liver [86]. Figure 8 presents a recent study showed the *in vivo* application of 450 nm Nevirapine nanocrystals in mice [87]. The study indicated an EPR effect in the liver of mice for the drug nanocrystals as compared to drug in solution. However, the size of drug nanocrystals significantly affects their dissolution and accumulation profiles. For instance, a study showed the use of nanocrystals of Oridonin drug with two sizes ranges; 100 nm and 900 nm. It was found that when these drug nanocrystals were IV injected in rabbits, the 100 nm nanocrystals showed complete dissolution within 10 minutes whereas the 900 nm nanocrystals underwent complete dissolution in 2 hours [88].




Figure 8: Particle-like behavior of NCs *in vivo*. (A) Gamma scintigrams depicting biodistribution of bare radiolabelled nevirapine 450-nm NCs and NCs surface-coated with albumin and dextran at 1 h and 24 h in rat compared to the drug in solution. (Reproduced with permission from reference [87])

### Benefits of nanosuspensions in drug delivery

There are several benefits of nanosuspensions for use in drug delivery applications, such as <sup>[89 - 91]</sup>:

- improves solubility of drugs insoluble in organic media and water, as alternative to lipid systems
- helps to decrease the dosage requirements by increasing absorption and bioavailability of drugs
- helps in formulations of high melting point and high log P value drugs
- reduces systemic toxicity of drugs
- increased physical stability of drugs
- offers high resistance to oxidation and hydrolysis
- offers passive targeting

### Conclusion

To this date, various types of nanoparticles are employed in the field of nanomedicine, for drug delivery, imaging, diagnostics and several other applications. Even though a large number of studies are dedicated towards the carrier molecules such as organic and inorganic nanoparticles, it is important to understand the physiochemical properties of the effective drug itself for both *in vivo* and *in vitro* studies. There are several different processes that are used for synthesising the drug nanoparticles in both crystalline and amorphous forms, but these processes are broadly classified as top down and bottom up approaches. It is therefore important to choose the right methods of nanosizing the drug to control the degree of crystallinity and properties like particle size, morphology and surface areas.

Nanosuspensions are an attractive solution for drug delivery, especially for oral and dermal routes of administration and are in turn favourable towards both amorphous and crystalline drug nanoparticles. It is highly anticipated that nanosuspension can dramatically improve the drug efficacy and bioavailability for all major drug classes, provided suitable solvents and stabilising agents are discovered. Therefore further studies should be directed towards finding a surfactant free route of drug delivery such as the food-derived or blood-derived proteins which poses no toxicity problems *in vivo*.

### Future Perspective

Targeted nanodrugs have already showed higher performance as compared to conventional drugs through almost all routes of administration. However the number of nanomedicines commercialising every year is far less than the total articles published. There seems to be a gap that is created between the laboratory tests and actual clinical trials due to the various differences that arise during scale up process and clinical trial stage. Therefore, adequate characterisation should be carried out for the synthesised drug nanoparticles and performance should be evaluated based on specific parameters such as surface area, surface charge and dispensability in nanosuspension. Foremost, crystallisation methods should be standardised for certain drug classes and appropriate control should be established on the aspect ratio of the drug nanocrystals for potential drug delivery both via passive and active targeting routes.

### Acknowledgements

Authors thank to UK India Education and Research Initiative (UKIERI) as this work has partly been supported by on-going project with the contract number DST/INT/UK/P-82/2014 as a part of project dissemination activity.

### Financial & Competing interests disclosures

*The authors have no relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.*

## Executive summary

### Fabrication of drug nanoparticles in suspension

- Drug particles in nanosuspension mitigate solubility and bioavailability issues of drugs.
- Two main approaches for the synthesis of nanosuspension such as top-down and bottom up.
- Crystalline and amorphous nanoparticle with variety of shapes, sizes and morphology can be designed
- A range of characterisation techniques can be used for tuning the properties of drug nanoparticles

### Nanosuspensions in Drug Delivery

- Poor solubility of drug molecules triggered the development of drug nanoparticulates for drug delivery
- Nanosuspensions are highly desirable for oral route of drug administration
- It is also compatible for parenteral routes of drug administration like intravenous, interperitoneal and intra-articular.
- Nebulising of nanosuspensions aids the drugs to be used for pulmonary routes
- Drug nanocrystals have higher EPR (enhanced permeability and retention) effect
- *In vitro* studies of drug nanocrystals are limited by agglomeration, crystal growth and sedimentation
- *In vivo* studies of drug nanocrystals face challenges due to bio-distribution and dissolution barriers along with accumulation tendencies in liver and spleen.

## References

The author have used the following keys to highlight the articles which are of "interest" and of "considerable interest"

\* = of interest, \*\* = of considerable interest

1. Varkony H, Weinstein V, Klinger E, et al.: The glatiramoid class of immunomodulator drugs. *Expert Opin. Pharmacother.* 10, 657–668 (2009)
2. Robinson DM, Keating GM: Colesevelam: a review of its use in hypercholesterolemia. *Am. J. Cardiovasc. Drugs.* 7 (6), 453–465 (2007)
3. MCGowan I, Gomez K, Bruder K, et al.: Phase 1 Randomized Trial of the Vaginal Safety and Acceptability of SPL7013 Gel (VivaGel®) in Sexually Active Young Women (MTN-004). *AIDS (London, England).* 25(8), 1057-1064 (2011)
4. Raggi P, Vukicevic S, Moyses RM, Wesseling K, Spiegel DM: Ten-year experience with sevelamer and calcium salts as phosphate binders. *Clin. J. Am. Soc. Nephrol.*, 5 (Suppl. 1), S31–40 (2010)
5. Brough C, Williams RO. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery. *Int J Pharmaceut* 453(1), 157-166 (2013).
6. Prabhakar C, Krishna KB: A review on nanosuspensions in drug delivery. *Internl. Journl. Pharm. & Bio Sci.* 2(1), 549–558 (2011)
7. Zhang L, Chen Z, Yang K, Liu C, Gao J, Qian F:  $\beta$ -Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy. *Mol. Pharmaceu.* 12, 3999–4010 (2015)
8. Chingunpituk J: Nanosuspension technology for drug delivery. *Walailak J. Sci. & Tech.* 4(2), 139–153 (2007)
9. Patravale VB, Date AA, Kulkarni RM: Nanosuspensions: a promising drug delivery strategy. *J. Pharm. Pharmaco.* 56(7), 827–840 (2004)
10. Junyaprasert VB, Morakul B: Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs, *Asian J. Pharmaceu. Sci.* 10(1), 13-23 (2015)
11. Magdalene R: Pure drug nanoparticles for the formulation of poorly soluble drugs. *NewDrugs.* 3, 62–68 (2001)
12. Möschwitzer J, Müller R.H: Drug nanocrystals – the universal formulation approach for poorly soluble drugs, D. Thassu, M. Deleers, Y. Pathak (Eds.), Nanoparticulate drug delivery systems, *Informa Healthcare.* 71–88, New York (2007)
13. Gao L, Zhang D, Chen M: Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system, *J Nanopart Res,* 10, 845–862 (2008)
14. Junghanns J.U.A.H, Müller R.H: Nanocrystal technology, drug delivery and clinical applications, *Int J Nanomedicine.* 3 (3), 295–309 (2008)
15. H. Chen, C. Khemtong, X. Yang, et al., Nanonization strategies for poorly water-soluble drugs, *Drug Discov Today,* 16 (7/8) (2011), pp. 354–360
16. Hosokawa M, Nogi K, Naito M, Yokoyama T: Nanoparticle Technology Handbook: Nanoparticles and Quantum dots, edited by Klaus D. Sattler, *CRC Press* (2011)

17. Wang GD, Mallet FP, Ricard F, Heng JYY. Pharmaceutical nanocrystals. *Curr Opin Chem Eng* 1(2), 102-107 (2012).  
\*\* The role of surface properties on drug's dissolution rate and targeted drug delivery is discussed in detail here. A special section is dedicated to the key technical challenges and environmental impact during drug nanocrystal processing.
18. Tuomela A, Saarinen J, Strachan CJ, Hirvonen J, Peltonen L. Production, applications and in vivo fate of drug nanocrystals. *J Drug Deliv Sci Tec* 34 21-31 (2016).
19. Banavath H, Raju KS, Ansari MT, Ali MS, Pattnaik G: Nanosuspension: an attempt to enhance bioavailability of poorly soluble drugs. *Intern. J. Pharmaceu. Sci. Res.* 1(9), 1-11 (2010)
20. Reddy GA, Anilchowdary Y: Nanosuspension technology: a review. *IJPI's J. Pharmaceu. Cosm.*, 2 (8), 47-52 (2012)
21. Parrot EL: Comminution. *Encycl. of Pharma. Tech.* 3, 101-121. Marcel Decker Inc., New York (1990)
22. Hütterauch R, Fricke S, Zielke P: Mechanical activation of pharmaceutical systems. *Pharm. Res.* 2, 302-306 (1985)  
\* The effects of milling on the drug nanocrystals are highlighted here, especially using paracetamol drug and studying its surface properties.
23. Heng JYY, Thielmann F, Williams DR: The effects of milling on the surface properties of form I paracetamol crystals. *Pharm. Res.* 23, 1918-1927 (2006)
24. Rabinow BE: Nanosuspensions in drug delivery. *Nat. Rev. Drug Discov.* 3, 785-796 (2004)
25. Date AA, Patravale VB: Current Strategies for engineering drug nanoparticles. *Curr. Opin. Colloid Interface Sci.* 9, 222-235 (2004)
26. Patel VR, Agrawal YK: Nanosuspension: An approach to enhance solubility of drugs. *J. Adv. Pharmaceu. Tech. & Res.*, 2(2), 81-87 (2011)
27. Romero GB, Arntjen A, Keck CM, Müller RH: Amorphous cyclosporin A nanoparticles for enhanced dermal bioavailability. *Int J Pharm.* 498(1-2), 217-224 (2016)
28. Tran TT, Tran PH, Nguyen MN, et al.: Amorphous isradipine nanosuspension by the sonoprecipitation method. *Int J Pharm.* 474(1-2), 146-150 (2014)
29. Hong C, Dang Y, Lin G, et al.: Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation. *Int J Pharm.* 477(1-2), 251-260 (2014)
30. Shin GH, Li J, Cho JH, Kim JT, Park HJ. Enhancement of Curcumin Solubility by Phase Change from Crystalline to Amorphous in Cur-TPGS Nanosuspension. *J Food Sci.* 81(2), N494-501 (2016)
31. Sharma P, Zujovic ZD, Bowmaker GA, Marshall AJ, Denny WA, Garg S: Evaluation of a crystalline nanosuspension: polymorphism, process induced transformation and in vivo studies. *Int J Pharm* 408(1-2), 138-151 (2011)
32. Aditya NP, Yang H, Kim S, Ko S: Fabrication of amorphous curcumin nanosuspensions using beta-lactoglobulin to enhance solubility, stability, and bioavailability. *Colloids Surf B Biointerfaces.* 127, 114-121 (2015)
33. Kumar S, Xu X, Gokhale R, Burgess DJ: Formulation parameters of crystalline nanosuspensions on spray drying processing: a DoE approach. *Int J Pharm.* 464(1-2), 34-45 (2014)
34. Beirowski J, Inghelbrecht S, Arien A, Gieseler H: Freeze drying of nanosuspensions, 2: the role of the critical formulation temperature on stability of drug nanosuspensions and its practical implication on process design. *J Pharm Sci.* 100(10), 4471-4481 (2011)

- 1  
2  
3 35. Ali HS, York P, Ali AM, Blagden N: Hydrocortisone nanosuspensions for  
4 ophthalmic delivery: A comparative study between microfluidic  
5 nanoprecipitation and wet milling. *J Control Release*. 149(2), 175-181 (2011)  
6  
7 36. Murdande SB, Shah DA, Dave RH: Impact of nanosizing on solubility and  
8 dissolution rate of poorly soluble pharmaceuticals. *J Pharm Sci*. 104(6), 2094-  
9 2102 (2015)  
10 37. Thombre AG, Shah JC, Sagawa K, Caldwell WB: In vitro and in vivo  
11 characterization of amorphous, nanocrystalline, and crystalline ziprasidone  
12 formulations. *Int J Pharm*. 428(1-2), 8-17 (2012)  
13 38. Zhang K, Yu H, Tang X., et al.: Increased dissolution and oral absorption of  
14 itraconazole/soluplus exrudate compared with itraconazole nanosuspension.  
15 *Euro. J. Pharamceu. Biopharma*. 85, 1285-1292 (2013)  
16 39. Dai WG, Dong LC, Song YQ: Nanosizing of a drug/carrageenan complex to  
17 increase solubility and dissolution rate. *Int J Pharm*. 342(1-2), 201-207 (2007)  
18 40. Thadkala K, Nanam PK, Rambabu B, Sailu C, Aukunuru J: Preparation and  
19 characterization of amorphous ezetimibe nanosuspensions intended for  
20 enhancement of oral bioavailability. *Int J Pharm Investig*. 4(3), 131-137 (2014)  
21 41. Zuo B, Sun Y, Li H et al.: Preparation and in vitro/in vivo evaluation of  
22 fenofibrate nanocrystals. *Int J Pharm*. 455(1-2), 267-275 (2013)  
23 42. Kumar S, Gokhale R, Burgess DJ: Quality by Design approach to spray drying  
24 processing of crystalline nanosuspensions. *Int J Pharm*. 464(1-2), 234-242  
25 (2014)  
26 43. Fissan H, Ristig S, Kaminski H, Asbach C, Epple M: Comparison of different  
27 characterization methods for nanoparticle dispersions before and after  
28 aerosolization, *Anal. Methods*, 6, 7324-7334 (2014)  
29 44. Sahu BP, Das MK: Nanosuspension for enhancement of oral bioavailability of  
30 felodipine, *App. Nanosci.*, 4(2), 189-197 (2014)  
31 45. Attari Z, Bhandari A, Jagadish PC, Lewis S: Enhanced ex vivo intestinal  
32 absorption of olmesartan medoxomil nanosuspension: Preparation by  
33 combinative technology, *Saudi Pharmaceu. J*. 24(1), 57-63 (2016)  
34 46. Mooter G: The use of amorphous solid dispersions: a formulation strategy to  
35 overcome poor solubility and dissolution rate. *Drug Discov Today Technol*. 9,  
36 e79-e85 (2012)  
37 47. Zhang M, Li H, Lang B, et al: Formulation and delivery of improved  
38 amorphous fenofibrate solid dispersion prepared by thin film freezing. *Eur J*  
39 *Pharm Biopharm.*, 82, 534-544 (2012)  
40 48. Shegokar R, Muller RH: Nanocrystals: industrially feasible multifunctional  
41 formulation technology for poorly soluble actives. *Int. J. Pharm*. 399(1-2),  
42 129-139 (2010)  
43 \* Bottom up and top down technologies are critically evaluated using various drug examples.  
44 Also, it focusses on smartCrystals and 2 main routes of administration (IV and Oral).  
45  
46 49. Talekar M, Ganta S, Amiji M et al: Development of PIK-75 nanosuspension  
47 formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-  
48 cancer therapy. *Int. J. Pharm*. 450(1-2), 278-289 (2013)  
49 50. Gao L, Zhang D, Chen M et al: Studies on pharmacokinetics and tissue  
50 distribution of oridonin nanosuspensions. *Int. J. Pharm*. 355(1-2), 321-327  
51 (2008)  
52 51. Liu G, Zhang D, Jiao Y et al.: In vitro and in vivo evaluation of riccardin D  
53 nanosuspensions with different particle size. *Colloids Surface. B* 102, 620-  
54 626 (2013)  
55  
56  
57  
58  
59  
60

- 1  
2  
3 52. Hao L, Wang X, Zhang D *et al.*: Studies on the preparation, characterization  
4 and pharmacokinetics of Amoitone B nanocrystals. *Int. J. Pharm.* 433(1–2),  
5 157–164 (2012)  
6  
7 53. Zheng D, Wang Y, Zhang D *et al.*: in vitro antitumor activity of silybin  
8 nanosuspension in PC-3 cells. *Cancer Lett.* 307(2), 158–164 (2011)  
9  
10 54. Wang Y, Ma Y, Zheng Y *et al.*: In vitro and in vivo anticancer activity of a  
11 novel puerarin nanosuspension against colon cancer, with high efficacy and  
12 low toxicity. *Int. J. Pharm.* 441(1–2), 728–735 (2013)  
13  
14 55. Lee SE, Bairstow SF, Werling JO *et al.*: Paclitaxel nanosuspensions for  
15 targeted chemotherapy – nanosuspension preparation, characterization, and  
16 use. *Pharm. Dev. Technol.* 19(4), 438–453 (2014)  
17  
18 56. Zhao YX, Hua HY, Chang M, Liu WJ, Zhao Y, Liu HM: Preparation and  
19 cytotoxic activity of hydroxycamptothecin nanosuspensions. *Int. J. Pharm.*  
20 392(1–2), 64–71 (2010)  
21  
22 57. Keck CM, Muller RH: Drug nanocrystals of poorly soluble drugs produced by  
23 high pressure homogenisation. *Eur. J. Pharm. Biopharm.* 62(1), 3–16 (2006)  
24  
25 58. Niwa T, Miura S, Danjo K: Universal wet-milling technique to prepare oral  
26 nanosuspension focused on discovery and preclinical animal studies –  
27 development of particle design method. *Int. J. Pharm.* 405, 218–227 (2011)  
28  
29 59. Merisko-Liversidge E, Liversidge GG: Nanosizing for oral and parenteral drug  
30 delivery: a perspective on formulating poorlywater soluble compounds using  
31 wet media milling technology. *Adv. Drug Deliv. Rev.* 63, 427–440 (2011)  
32  
33 60. Hollis CP, Li T: Nanocrystals production, characterization, and application for  
34 cancer therapy. In: *Nanoparticulate Drug Delivery Systems: Strategies,*  
35 *Technologies, and Applications.* Yeo Y (Ed.). *John Wiley & Sons, Inc., NY,*  
36 *USA,* 181–206 (2013)  
37  
38 61. Luque De Castro MD, Priego-Capote F: Ultrasound-assisted crystallization  
39 (sonocrystallization). *Ultrason. Sonochem.* 14(6), 717–724 (2007)  
40  
41 62. Sinha B, Muller RH, Moschwitz JP: Bottom-up approaches for preparing  
42 drug nanocrystals: formulations and factors affecting particle size. *Int. J.*  
43 *Pharm.* 453, 126–141 (2013)  
44  
45 \*\* Various bottom up methodologies were critically discussed, followed by several process  
46 parameters which affect the particle size of drug nanocrystals.  
47  
48 63. Nie FL, Zheng YF, Wei SC, Wang DS, Yu ZT, Salimgareeva GK, Polyakov  
49 AV, Valiev RZ: In vitro and in vivo studies on nanocrystalline Ti fabricated by  
50 equal channel angular pressing with microcrystalline CP Ti as control. *J*  
51 *Biomed Mater Res Part A,* 101A, 1694–1707 (2013)  
52  
53 64. Merisko-Liversidg E: Nanosizing:“End-to-End” Formulation Strategy for Poorly  
54 Water-Soluble Molecules. *Discov. Devel. Mol. with Opt. Drug-Like Prop.* 437-  
55 467, Springer New York (2015)  
56  
57 65. Gao L, Liu G, Ma J *et al.*: Application of drug nanocrystal technologies on oral  
58 drug delivery of poorly soluble drugs. *Pharm. Res.* 30(2), 307–324 (2013)  
59  
60 66. Merisko-Liversidge E, Sarpotdar P, Bruno J *et al.*: Formulation and antitumor  
activity evaluation of nanocrystalline suspensions of poorly soluble anticancer  
drugs. *Pharm. Res.* 13(2), 272–278 (1996)  
67. Xia D, Quan P, Piao H *et al.*: Preparation of stable nitrendipine  
nanosuspensions using the precipitation-ultrasonication method for  
enhancement of dissolution and oral bioavailability. *Eur. J. Pharm. Sci.* 40(4),  
325–334 (2010)

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
68. Chong-Hui G, Grant DJW: Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data. *J Pharmacol Sci.* 909, 1277–87 (2001)
69. Hancock BC, Parks M: What is the true solubility advantage for amorphous pharmaceuticals? *Pharmacol Res.* 174, 397–404 (2000)
70. Vaghela A, Jain M, Limbachiya H, Bharadia DP: Nanosuspension technology. *Intern. J. Univ. Pharm. and Life Sci.* 2(2), 306–317 (2012)
71. Pawar VK, Singh Y, Meher JG, Gupta S, Chourasia MK. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery. *J Control Release* 183 51-66 (2014).  
\* *In vivo fate and various routes of administration are discussed using various drug nanocrystal studies that focus on engineering the drug nanoparticles.*
72. Merisko-Liversidge E, Liversidge GG, Cooper ER: Nanosizing: a formulation approach for poorly-water-soluble compounds. *Euro. J. Pharmaceu. Sci.*, 18, (2), 113–120 (2003)
73. Kayser O, Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages. *Intern. J. Pharmaceu.* 196(2), 253–256 (2000)
74. Peters K, Leitzke S, Diederichs JE, *et al.*: Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. *J. Antimicro. Chemo.*, 45(1), 77–83 (2000)
75. Rabinow BE: Nanosuspensions for parenteral delivery. *Nanoparticulate Drug Delivery Systems*, 33–49, Informa Healthcare, London, UK (2007)
76. McMillan J, Batrakova E, Gendelman HE: Cell delivery of therapeutic nanoparticle. *Prog. in Molec. Bio. and Translat. Sci.* 104, 571–572, Elsevier, New York, NY, USA (2011)
77. Willart JF, Descamps M. Solid State Amorphization of Pharmaceuticals. *Mol Pharmaceut* 5(6), 905-920 (2008).
78. Kayaert P, Anne M, Van Den Mooter G. Bead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in-vitro release from sugar beads. *J Pharm Pharmacol* 63(11), 1446-1453 (2011).
79. Liu F, Park JY, Zhang Y *et al.* Targeted Cancer Therapy With Novel High Drug-Loading Nanocrystals. *J Pharm Sci-Us* 99(8), 3542-3551 (2010).
80. Zhang H, Hollis CP, Zhang Q, Li TL. Preparation and antitumor study of camptothecin nanocrystals. *Int J Pharmaceut* 415(1-2), 293-300 (2011).  
\*\* *Effect of crystallisation on the bioavailability and solubility of antitumor drug Camptothecin is demonstrated, as compared to drug salt solution.*
81. Nowacek AS, Mcmillan J, Miller R, Anderson A, Rabinow B, Gendelman HE. Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics. *J Neuroimmune Pharm* 5(4), 592-601 (2010).
82. Nowacek AS, Balkundi S, Mcmillan J *et al.* Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. *J Control Release* 150(2), 204-211 (2011).
83. Muller RH, Gohla S, Keck CM. State of the art of nanocrystals - Special features, production, nanotoxicology aspects and intracellular delivery. *Eur J Pharm Biopharm* 78(1), 1-9 (2011).

- 1  
2  
3 84. Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. *Expert Opin Drug Del* 8(3), 343-357 (2011).
- 4  
5  
6 85. Tian XN, Li H, Zhang DR *et al.* Parenteral nanosuspension of a novel synthesized antitumor candidate: Investigation of tissue biodistributions and plasma pharmacokinetics. *Colloid Surface A* 436 868-872 (2013).
- 7  
8  
9 \* Plasma pharmacokinetics and tissue biodistribution studies were done using in vivo mice model and a parenteral nanosuspension for antitumor targeted drug delivery.
- 10  
11 86. Tian XN, Li H, Zhang DR *et al.* Nanosuspension for parenteral delivery of a p-terphenyl derivative: Preparation, characteristics and pharmacokinetic studies. *Colloid Surface B* 108 29-33 (2013).
- 12  
13  
14 87. Shegokar R, Singh KK. Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation. *Int J Pharmaceut* 421(2), 341-352 (2011).
- 15  
16  
17 \* Antiviral drug Nevirapine was used as a model drug to formulate surface modified nanosuspension and study the EPR effect and biodistribution, when administered IV into rat model
- 18  
19  
20 88. Gao L, Zhang DR, Chen MH *et al.* Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. *Int J Pharmaceut* 355(1-2), 321-327 (2008).
- 21  
22  
23 89. Verma S, Lan Y, Gokhale R, Burgess DJ: Quality by design approach to understand the process of nanosuspension preparation, *Intern. J. Pharmaceu.* 377 (1-2), 185-198 (2009)
- 24  
25  
26 90. Liu P, Rong X, Laru J, *et al.*: Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. *Intern. J. Pharmaceu.* 411(1-2), 215-222 (2011)
- 27  
28  
29 91. Ibrahim HM, Ismail HR, Lila AEA, *et al.*: Formulation and optimization of ocular poly-D, L-lactic acid nano drug delivery system of amphotericin-B using box behnken design. *Intern. J. Pharm. Pharmaceu. Sci.*, 4(2), 342-349 (2012)
- 30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60